FORM 6-K
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Report of Foreign Private Issuer
Pursuant to Rule 13s - 16 or 15d - 16 of
the Securities Exchange Act of 1934
For the month of April, 2006
Acambis plc
(Translation of registrant's name into English)
Peterhouse Technology Park
100 Fulbourn Road
Cambridge CB1 9PT
England
(address of principal executive offices)
(Indicate by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F
Forms 20-F X Form 40-F
Indicate by check mark whether the registrant by furnishing the information
contained in this Form also thereby furnishing the information to the
Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934).
Yes No X
(if "Yes" is marked, indicate below the file number assigned to the registrant
in connection with Rule 12g3-2(b): 82- ).
Enclosure:
1. Holding(s) in Company
2. Holding(s) in Company
3. Notice of Results
SCHEDULE 10
NOTIFICATION OF MAJOR INTERESTS IN SHARES
1. Name of company
Acambis plc
2. Name of shareholder having a major interest
HBOS plc
3. Please state whether notification indicates that it is in respect of holding
of the shareholder named in 2 above or in respect of a non-beneficial interest
or in the case of an individual holder if it is a holding of that person's
spouse or children under the age of 18
As above
4. Name of the registered holder(s) and, if more than one holder, the number of
shares held by each of them
The legal entities holding these shares are as follows:
HSDL Nominees Limited - 33 shares
State Street Nominees Limited a/d 2GEH - 92,500 shares
State Street Nominees Limited a/d 2GDX - 107,500 shares
State Street Nominees Limited a/d 2GEG - 570,000 shares
State Street Nominees Limited a/d 2GDW - 690,000 shares
State Street Nominees Limited a/d 2GDS - 1,800,000 shares
5. Number of shares / amount of stock acquired
Not disclosed
6. Percentage of issued class
Not disclosed
7. Number of shares / amount of stock disposed
N/A
8. Percentage of issued class
N/A
9. Class of security
Ordinary shares of 10p each
10. Date of transaction
Not disclosed
11. Date company informed
3 April 2006
12. Total holding following this notification
3,260,033 shares
13. Total percentage holding of issued class following this notification
3.04%
14. Any additional information
N/A
15. Name of contact and telephone number for queries
Elizabeth Brown tel: 01223 275300
16. Name and signature of authorised company official responsible for making
this notification
Elizabeth Brown, Company Secretary
Date of notification
3 April 2006
The FSA does not give any express or implied warranty as to the accuracy of this
document or material and does not accept any liability for error or omission.
The FSA is not liable for any damages (including, without limitation, damages
for loss of business or loss of profits) arising in contract, tort or otherwise
from the use of or inability to use this document, or any material contained in
it, or from any action or decision taken as a result of using this document or
any such material.
SCHEDULE 10
NOTIFICATION OF MAJOR INTERESTS IN SHARES
1. Name of company
Acambis plc
2. Name of shareholder having a major interest
Phylon Fund Limited
3. Please state whether notification indicates that it is in respect of holding
of the shareholder named in 2 above or in respect of a non-beneficial interest
or in the case of an individual holder if it is a holding of that person's
spouse or children under the age of 18
As above
4. Name of the registered holder(s) and, if more than one holder, the number of
shares held by each of them
The legal entity holding these shares is:
Goldman Sachs Security Nominees Limited
5. Number of shares / amount of stock acquired
772,000 shares
6. Percentage of issued class
0.72%
7. Number of shares / amount of stock disposed
N/A
8. Percentage of issued class
N/A
9. Class of security
Ordinary shares of 10p each
10. Date of transaction
18 and 19 April 2006
11. Date company informed
19 April 2006
12. Total holding following this notification
3,922,000 shares
13. Total percentage holding of issued class following this notification
3.65%
14. Any additional information
N/A
15. Name of contact and telephone number for queries
Elizabeth Brown tel: 01223 275300
16. Name and signature of authorised company official responsible for making
this notification
Elizabeth Brown, Company Secretary
Date of notification
20 April 2006
The FSA does not give any express or implied warranty as to the accuracy of this
document or material and does not accept any liability for error or omission.
The FSA is not liable for any damages (including, without limitation, damages
for loss of business or loss of profits) arising in contract, tort or otherwise
from the use of or inability to use this document, or any material contained in
it, or from any action or decision taken as a result of using this document or
any such material.
Notice of results
Cambridge, UK and Cambridge, Massachusetts - 28 April 2006 - Acambis plc
("Acambis") (LSE: ACM, NASDAQ: ACAM) will announce its results for the first
quarter ended 31 March 2006 on Tuesday, 9 May.
The results announcement will be released at 7.00 am BST. A conference call for
analysts will be held at 9.00 am BST. For details, please contact Mo Noonan at
Financial Dynamics on telephone number +44 (0) 20 7269 7116. An instant replay
of the call will be available until 16 May 2006 on telephone number UK: +44 (0)
20 7365 8427 and US: +1 617 801 6888. The pin code is 47328347.
An audio webcast of the call will also be available via Acambis' website at
www.acambis.com. The webcast replay will be available for 12 months until 9 May
2007.
-ends-
Enquiries:
Acambis plc
Lyndsay Wright, VP, Communications and Investor Relations:
Tel +44 (0) 1223 275 300
Financial Dynamics
Mo Noonan: Tel +44 (0) 20 7269 7116
About Acambis
Acambis is a leading developer of vaccines to prevent and treat infectious
diseases. Recognised internationally as the leading producer of smallpox
vaccines, Acambis is developing an investigational smallpox vaccine and
manufacturing emergency-use stockpiles of this investigational vaccine for the
US Government and other governments around the world. Acambis is establishing a
travel vaccines franchise through its US-based subsidiary Berna Products
Corporation, which markets Vivotif(R), the world's only licensed oral typhoid
vaccine, in North America. Acambis has a number of other potential travel
vaccines in development and is also developing an investigational vaccine
against the West Nile virus, which has spread to 47 US States in the last six
years.
Acambis is based in Cambridge, UK and Cambridge, Massachusetts, US. Its primary
listing is on the London Stock Exchange (ACM) and its shares are listed in the
form of American Depositary Receipts on NASDAQ (ACAM). More information is
available at www.acambis.com.
"Safe Harbor" statement under the Private Securities Litigation Reform Act of
1995:
The statements in this news release that are not historical facts are
forward-looking statements that involve risks and uncertainties, including the
timing and results of clinical trials, product development, manufacturing and
commercialisation risks, the risks of satisfying the regulatory approval process
in a timely manner, the need for and the availability of additional capital. For
a discussion of these and other risks and uncertainties see "Risk management" in
the Company's 2004 Annual Report and 2003 Form 20-F, in addition to those
detailed on the Company's website and in the Company's filings made with the
Securities and Exchange Commission from time to time. These forward-looking
statements are based on estimates and assumptions made by the management of
Acambis and are believed to be reasonable, though are inherently uncertain and
difficult to predict. Actual results or experience could differ materially from
the forward-looking statements.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant Peptide Therapeutics Group has duly caused this report to be
signed on its behalf by the undersigned, thereunto duly authorized.
Date: 02 May, 2006 ACAMBIS PLC
By: /s/ Lyndsay Wright
Name: Lyndsay Wright
Title: VP, Communications and IR.